Immune Targeting Systems (ITS) Ltd. Secures An £8.65m Series A Extension To Fund FP-01, Its Synthetic Universal Flu … (Medical News Today)
February 18, 2010 — JesseImmune Targeting Systems (ITS) Limited (“ITS”), one of the leading developers of synthetic vaccines for mutating viruses, announced it had secured a Series-A equity funding round extension for £8.65m which brings the total Series A financing to £13.15m. The company’s key investors HealthCap (Sweden), London Technology Fund (UK), Novartis Venture Fund (US & Basel) and Truffle Capital (France …
Originally posted here:
Immune Targeting Systems (ITS) Ltd. Secures An £8.65m Series A Extension To Fund FP-01, Its Synthetic Universal Flu … (Medical News Today)